Expert Opinion on Orphan Drugs
Volume 12, 2024 - Issue 1
Open access
302
Views
0
CrossRef citations to date
0
Altmetric
Original Research
The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022
Abraham Viju Ipea Pediatrics, Children’s National Hospital, Washington DC, USAView further author information
, Lewis J. Fermaglichb Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USACorrespondence[email protected]
View further author information
, View further author information
Selma Kraftb Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USAView further author information
, Catherine Measeb Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USAView further author information
, Tran Leb Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USAView further author information
& Kathleen L. Millerc Division of Science and Public Health Policy, Office of Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services, Washington DC, USAView further author information
Pages 12-18
|
Received 27 Nov 2023, Accepted 18 Mar 2024, Published online: 26 Mar 2024
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.